Antibiotic resistant infections like gonorrhoea could soon be treated by cannabis, as breakthrough research suggests the drug could be a potentially powerful tool in combating superbugs.
Synthetic cannabidiol, or CBD, has for the first time shown it is capable of killing the bacteria responsible for gonorrhoea, meningitis and legionnaires disease, according to the University of Queensland.
There is no single, reliable antibiotic available to treat gonorrhoea – the second most common sexually transmitted infection in Australia – because the bacteria is extremely capable of developing resistance, but CBD oil could be its match.
The research, under a joint partnership with Botanix Pharmaceuticals, could lead to the first new class of antibiotics for resistant bacteria in 60 years. But scientists say there’s a lot more research that needs to be done before any treatment is rolled out.
UQ Associate Professor Mark Blaskovich said CBD, which is the main non-psychoactive component of the drug, could penetrate and kill “a wide range of bacteria”.
“This is the first time CBD has been shown to kill some types of Gram-negative bacteria,” he said.
“These bacteria have an extra outer membrane, an additional line of defence that makes it harder for antibiotics to penetrate.”
The study also showed that CBD was widely effective against a much larger number of Gram-positive…
Original Author Link click here to read complete story..
Antibiotic resistant infections like gonorrhoea could soon be treated by cannabis, as breakthrough research suggests the drug could be a potentially powerful tool in combating superbugs.
Synthetic cannabidiol, or CBD, has for the first time shown it is capable of killing the bacteria responsible for gonorrhoea, meningitis and legionnaires disease, according to the University of Queensland.
There is no single, reliable antibiotic available to treat gonorrhoea – the second most common sexually transmitted infection in Australia – because the bacteria is extremely capable of developing resistance, but CBD oil could be its match.
The research, under a joint partnership with Botanix Pharmaceuticals, could lead to the first new class of antibiotics for resistant bacteria in 60 years. But scientists say there’s a lot more research that needs to be done before any treatment is rolled out.
UQ Associate Professor Mark Blaskovich said CBD, which is the main non-psychoactive component of the drug, could penetrate and kill “a wide range of bacteria”.
“This is the first time CBD has been shown to kill some types of Gram-negative bacteria,” he said.
“These bacteria have an extra outer membrane, an additional line of defence that makes it harder for antibiotics to penetrate.”
The study also showed that CBD was widely effective against a much larger number of Gram-positive…
